Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2024
0mins
Should l Buy CMPS?
Source: Benzinga
- DEA Revisiting Classification of Psychedelic Compounds: The DEA is reconsidering the classification of two psychedelic compounds, DOI and DOC, proposing to list them as Schedule I substances under the Controlled Substances Act.
- Passing of Russell Newcombe: April 4 marked the passing of Russell Newcombe, a significant figure in harm reduction advocacy and drug research globally.
- Benzinga Psychedelics Podcast Episode: Stephanie Wang, founder of KA! Empathogenics, discussed alternative mental health approaches using plant medicine like kanna on the Benzinga Psychedelics Podcast.
- Atai Life Sciences Results: Atai Life Sciences shared its Q4 and full-year 2023 results.
- Stock Market Updates: Various companies in the psychedelics sector such as Mind Medicine, COMPASS Pathways, and Atai Life Sciences saw fluctuations in their stock prices according to Benzinga Pro data.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.620
Low
8.00
Averages
18.43
High
40.00
Current: 5.620
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
COMPASS PATHWAYS RELEASES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2025
Fourth Quarter Financial Results: Compass Pathways has announced its financial results for the fourth quarter of 2025, highlighting key performance metrics and financial health.
Full-Year Highlights: The company also provided a summary of its full-year performance for 2025, showcasing significant business achievements and milestones reached throughout the year.
See More
COMP360 Achieves Breakthrough in Treatment-Resistant Depression
- Clinical Trial Success: COMP360 has achieved significant results in three large clinical trials for treatment-resistant depression (TRD), including two positive Phase 3 studies, potentially offering new treatment options for the approximately 200,000 patients currently underserved in the U.S.
- FDA Meeting Scheduled: Compass is set to meet with the FDA to confirm its NDA submission strategy, with expectations to complete the submission by Q4 2026, which will accelerate the market launch of COMP360 to address the growing mental health needs.
- Financial Backing: Compass successfully raised $150 million in February 2025 and exercised $200 million in warrants, extending its cash runway into 2028, thereby providing a solid foundation for the commercialization of COMP360.
- PTSD Study Initiation: The FDA has accepted the IND application for COMP360, initiating a Phase 2b/3 trial for post-traumatic stress disorder (PTSD), further expanding its application in mental health and addressing the urgent needs of 13 million Americans affected annually.
See More
COMPASS Pathways Reports Earnings and Financing Details
- Earnings Miss: COMPASS Pathways reported a Q4 GAAP EPS of -$1.00, missing expectations by $0.59, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, the company's cash and cash equivalents stood at $149.6 million, down from $165.1 million in 2024, reflecting pressure on cash management that could limit future investment capabilities.
- Debt Increase: COMPASS's debt as of December 31, 2025, was $31.6 million, up from $30.2 million in 2024, indicating challenges in debt management that may impact financial flexibility.
- Financing Initiatives: COMPASS Pathways raised $200 million through warrant exercises and plans to price a $150 million ADS offering, demonstrating proactive measures in capital raising to support future operational and capital expenditure needs.
See More
COMPASS PATHWAYS REPORTS Q4 OPERATING EXPENSES OF USD 45.952 MILLION
- Financial Overview: The operating expenses for Compass Pathways in Q4 amounted to USD 45.952 million.
- Company Focus: The company continues to prioritize its research and development efforts in the mental health sector.
See More
Compass Pathways to Attend Stifel 2026 Virtual CNS Forum
- Management Participation: Compass Pathways plc will attend the Stifel 2026 Virtual CNS Forum from March 17-18, 2026, with management participating in a fireside chat on March 18 at 10:30am ET, showcasing the company's innovations in mental health.
- Webcast Availability: The event will be accessible via a live audio webcast from the 'Events' page of the Compass website, with a replay available for 30 days post-event, ensuring investors can access critical information.
- Innovative Treatment Approach: Compass Pathways is pioneering innovation in mental health through its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA, aiming to provide new options for treatment-resistant depression patients.
- Global Presence: Headquartered in London, UK, with an office in New York, the company demonstrates its strategic vision to drive mental health innovation globally, aiming to assist patients who have not benefited from existing treatments.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
COMPASS PATHWAYS RELEASES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2025
Fourth Quarter Financial Results: Compass Pathways has announced its financial results for the fourth quarter of 2025, highlighting key performance metrics and financial health.
Full-Year Highlights: The company also provided a summary of its full-year performance for 2025, showcasing significant business achievements and milestones reached throughout the year.
See More
COMP360 Achieves Breakthrough in Treatment-Resistant Depression
- Clinical Trial Success: COMP360 has achieved significant results in three large clinical trials for treatment-resistant depression (TRD), including two positive Phase 3 studies, potentially offering new treatment options for the approximately 200,000 patients currently underserved in the U.S.
- FDA Meeting Scheduled: Compass is set to meet with the FDA to confirm its NDA submission strategy, with expectations to complete the submission by Q4 2026, which will accelerate the market launch of COMP360 to address the growing mental health needs.
- Financial Backing: Compass successfully raised $150 million in February 2025 and exercised $200 million in warrants, extending its cash runway into 2028, thereby providing a solid foundation for the commercialization of COMP360.
- PTSD Study Initiation: The FDA has accepted the IND application for COMP360, initiating a Phase 2b/3 trial for post-traumatic stress disorder (PTSD), further expanding its application in mental health and addressing the urgent needs of 13 million Americans affected annually.
See More
COMPASS Pathways Reports Earnings and Financing Details
- Earnings Miss: COMPASS Pathways reported a Q4 GAAP EPS of -$1.00, missing expectations by $0.59, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, the company's cash and cash equivalents stood at $149.6 million, down from $165.1 million in 2024, reflecting pressure on cash management that could limit future investment capabilities.
- Debt Increase: COMPASS's debt as of December 31, 2025, was $31.6 million, up from $30.2 million in 2024, indicating challenges in debt management that may impact financial flexibility.
- Financing Initiatives: COMPASS Pathways raised $200 million through warrant exercises and plans to price a $150 million ADS offering, demonstrating proactive measures in capital raising to support future operational and capital expenditure needs.
See More
COMPASS PATHWAYS REPORTS Q4 OPERATING EXPENSES OF USD 45.952 MILLION
- Financial Overview: The operating expenses for Compass Pathways in Q4 amounted to USD 45.952 million.
- Company Focus: The company continues to prioritize its research and development efforts in the mental health sector.
See More
Compass Pathways to Attend Stifel 2026 Virtual CNS Forum
- Management Participation: Compass Pathways plc will attend the Stifel 2026 Virtual CNS Forum from March 17-18, 2026, with management participating in a fireside chat on March 18 at 10:30am ET, showcasing the company's innovations in mental health.
- Webcast Availability: The event will be accessible via a live audio webcast from the 'Events' page of the Compass website, with a replay available for 30 days post-event, ensuring investors can access critical information.
- Innovative Treatment Approach: Compass Pathways is pioneering innovation in mental health through its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA, aiming to provide new options for treatment-resistant depression patients.
- Global Presence: Headquartered in London, UK, with an office in New York, the company demonstrates its strategic vision to drive mental health innovation globally, aiming to assist patients who have not benefited from existing treatments.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
